UK Markets closed
NIKKEI 225
27,606.46 -79.01 (-0.29%) HANG SENG
21,283.52 -15.18 (-0.07%) CRUDE OIL
78.40 +1.26 (+1.63%) GOLD FUTURES
1,887.70 +2.90 (+0.15%) DOW
33,949.01 -207.68 (-0.61%) BTC-GBP
18,980.51 -366.08 (-1.89%)
Oxford BioDynamics Plc (OBD.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 04:47PM GMT
| Previous close | 16.92 |
| Open | 17.77 |
| Bid | 17.40 x 0 |
| Ask | 19.70 x 0 |
| Day's range | 17.55 - 20.51 |
| 52-week range | 10.98 - 29.90 |
| Volume | |
| Avg. volume | 251,095 |
| Market cap | 27.692M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.70 |
| Earnings date | 23 Jan 2023 - 27 Jan 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 175.00 |
- Business Wire
Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men
OXFORD, England, February 06, 2023--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD’s technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk population. These results were referred to in the recent results statement.
- Simply Wall St.
The Non-Executive Director of Oxford BioDynamics Plc (LON:OBD), Stephen Diggle, Just Bought A Few More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Oxford BioDynamics Plc ( LON:OBD...
- Simply Wall St.
Oxford BioDynamics Full Year 2022 Earnings: UK£0.067 loss per share (vs UK£0.072 loss in FY 2021)
Oxford BioDynamics ( LON:OBD ) Full Year 2022 Results Key Financial Results Net loss: UK£6.71m (flat on FY 2021...
© 2023 Yahoo. All rights reserved.
